Onyx
-
S*BIO and Onyx Pharmaceuticals Expand Collaboration for JAK2 Inhibitors
S*BIO and Onyx Pharmaceuticals have announced the expansion of their development collaboration and option and license commercialization agreement for the former’s JAK2 inhibitors, SB1518 and SB1578, also known as ONX 0803 and ONX 0805, respectively…
Onyx | 19 May 2010
-
S*BIO Announces Collaboration with Onyx for JAK2 Inhibitors
S*BIO has announced that it has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals to develop and commercialize S*BIO’s JAK2 inhibitors, SB1518 and SB1578. Under the terms of the agreement, S*BIO i…
Onyx | 08 January 2009
-
Bayer, Onyx Updates On Phase III Trial of Nexavar
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. said a Phase III trial evaluating Nexavar (sorafenib) tablets in patients with non-small cell lung cancer (NSCLC) was stopped early following a planned interim analysis, when the indepen…
Onyx | 07 March 2008
